Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Cellectis    ALCLS   FR0010425595

CELLECTIS

(ALCLS)
  Report
Real-time Quote. Real-time Euronext Growth Paris - 01/15 11:39:44 am
25.5 EUR   -0.78%
01/14European ADRs Climb Higher in Thursday Trading
MT
01/13European ADRs Move Lower in Wednesday Trading
MT
01/11European ADRs Move Sharply Lower in Monday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cellectis : Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice President, Chief Human Resources Officer

11/17/2020 | 04:35am EST

New York (N.Y.) - Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Kyung Nam-Wortman as Cellectis' Executive Vice President, Chief Human Resources Officer. Ms. Nam-Wortman, who will be based in Cellectis'New York office, is also joining the Company's executive committee.

"Ky is an accomplished human resources leader who brings over 25 years of experience in the biotech/biopharma industries to Cellectis. She will lead Cellectis' human resources strategies and contribute to the Company's overarching mission, which will ultimately help drive our business toward commercialization," said Dr. Andre Choulika, Chief Executive Officer, Cellectis. "Furthermore, Ky has worked globally with some of the most successful biopharma companies and has an extensive background specializing in multiple areas of human resources. Her vast experience working with biotech leaders across the board to maximize human capital will make her an invaluable asset to our growing team."

In her new role at Cellectis, Ms. Nam-Wortman will work closely with Dr. Choulika and the executive management team to ensure that the Company advances its roadmap through the recruitment and retention of top talent. She will also work to further develop and enhance Cellectis' dynamic and inclusive culture, while optimizing the Company's human resources function.

Kyung Nam-Wortman joins Cellectis from Achillion (recently acquired by Alexion in January 2020) where she served as Senior Vice President, Head of Human Resources, Head of Information Technology, Facilities and Internal Communications. At Achillion, she was responsible for leading the strategic and operational components of the aforementioned functions.

Prior to her tenure at Achillion, Ms. Nam-Wortman served as Vice President and Head of Global Talent and Organization Capability at Zoetis, where she supported the spin-off of Pfizer's animal health business unit through its IPO and was responsible for the stand up of Zoetis' global talent management function to support the company's growth worldwide. She also held various human resource leadership roles for Pfizer's business units, divisions, and functions with regional and global accountabilities.

In addition to her experience in biotech/biopharma, Ms. Nam-Wortman has 14 years of experience in the consulting industry focused on strategic and organization change management from Delta Consulting Group and IBM. She received her bachelor's in marketing from New York University Stern School of Business and MS in human resources management / organization development from the New School of Social Research.

"From Day One, Cellectis' commitment to developing a cure for cancer patients in need utilizing its novel gene-editing technology has resonated deeply with me. I look forward to working with the team to help shape the future of the Company," said Ms. Nam-Wortman. "The success of any company ultimately starts with its people and culture. Continuing to find and develop the right talent for such a purpose-driven organization will be of the utmost importance for me, and ultimately, for Cellectis moving forward." Download the PDF file

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

All news about CELLECTIS
01/14European ADRs Climb Higher in Thursday Trading
MT
01/13European ADRs Move Lower in Wednesday Trading
MT
01/11European ADRs Move Sharply Lower in Monday Trading
MT
01/08CELLECTIS : Corporate Presentation January 2021
PU
01/08European ADRs Nudge Higher in Friday Trading
MT
2020European ADRs Move Lower in Thursday Trading
MT
2020CELLECTIS : Monthly statement on outstanding equity shares and voting rights
CO
2020European ADRs Move Higher in Wednesday Trading
MT
2020European ADRs Move Higher in Monday Trading
MT
2020ALLOGENE THERAPEUTICS : Receives IND Clearance from the U.S. Food and Drug Admin..
AQ
More news
Financials
Sales 2020 53,4 M 64,6 M 64,6 M
Net income 2020 -74,3 M -89,9 M -89,9 M
Net cash 2020 161 M 195 M 195 M
P/E ratio 2020 -9,33x
Yield 2020 -
Capitalization 1 099 M 1 335 M 1 330 M
EV / Sales 2020 17,6x
EV / Sales 2021 15,2x
Nbr of Employees 259
Free-Float 83,2%
Chart CELLECTIS
Duration : Period :
Cellectis Technical Analysis Chart | ALCLS | FR0010425595 | MarketScreener
Technical analysis trends CELLECTIS
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 27,35 €
Last Close Price 25,70 €
Spread / Highest target 13,6%
Spread / Average Target 6,42%
Spread / Lowest Target -0,78%
EPS Revisions
Managers and Directors
NameTitle
André Choulika Chief Executive Officer
Jean-Pierre Garnier Non-Executive Chairman
Eric Dutang Chief Financial Officer
Philippe Duchateau Chief Scientific Officer
Francisco J. Esteva Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CELLECTIS5.33%1 335
MODERNA, INC.24.17%51 332
LONZA GROUP AG3.31%49 176
CELLTRION, INC.-8.36%43 849
IQVIA HOLDINGS INC.4.99%36 066
SEAGEN INC.0.41%31 812